WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407806

CAS#: 1428339-47-2

Description: V-11-0711 is a Chk-α inhibitor. V-11-0711 reduced the function of Chk-α by binding to the active site and inhibiting the catalytic activity but did not affect Chk-α protein levels. Chk-α protein and PtdCho, but not PC, may be essential in cancer cell proliferation.

Price and Availability




V-11-0711 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 407806
Name: V-11-0711
CAS#: 1428339-47-2
Chemical Formula: C27H35NO3
Exact Mass: 421.2617
Molecular Weight: 421.581
Elemental Analysis: C, 76.92; H, 8.37; N, 3.32; O, 11.39

Related CAS #: 1428338-79-7 (R-isomer)   1428339-47-2  

Synonym: V-11-0711; V11-0711; V 11-0711; V-110711; V110711; V 110711.

IUPAC/Chemical Name: (1S)-1-phenyl-1-((1R,4R)-quinuclidin-3-yl)-3-(2-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)propan-1-ol


InChi Code: InChI=1S/C27H35NO3/c29-27(23-7-2-1-3-8-23,25-20-28-16-11-21(25)12-17-28)15-10-22-6-4-5-9-26(22)31-24-13-18-30-19-14-24/h1-9,21,24-25,29H,10-20H2/t25?,27-/m1/s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information

Phosphatidylcholine (PtdCho) has important roles in membrane structure and cell signaling. Increased levels of choline kinase (Chk)-α, the enzyme that converts choline to phosphocholine (PC) in the PtdCho biosynthesis, and PC are consistently observed in aggressive cancers including breast cancer [1-3]. Understanding the roles of Chk-α in cancer can result in new therapies.


1: Koch K, Hartmann R, Schröter F, Suwala AK, Maciaczyk D, Krüger AC, Willbold D,
Kahlert UD, Maciaczyk J. Reciprocal regulation of the cholinic phenotype and
epithelial-mesenchymal transition in glioblastoma cells. Oncotarget. 2016 Nov
8;7(45):73414-73431. doi: 10.18632/oncotarget.12337. PubMed PMID: 27705917;
PubMed Central PMCID: PMC5341988.

2: Mori N, Wildes F, Kakkad S, Jacob D, Solaiyappan M, Glunde K, Bhujwalla ZM.
Choline kinase-α protein and phosphatidylcholine but not phosphocholine are
required for breast cancer cell survival. NMR Biomed. 2015 Dec;28(12):1697-706.
doi: 10.1002/nbm.3429. Epub 2015 Oct 27. PubMed PMID: 26503172.

3: Falcon SC, Hudson CS, Huang Y, Mortimore M, Golec JM, Charlton PA, Weber P,
Sundaram H. A non-catalytic role of choline kinase alpha is important in
promoting cancer cell survival. Oncogenesis. 2013;2:e38. PubMed PMID: 25522435;
PubMed Central PMCID: PMC3641355.